NCT00652106 - Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension | Biotech Hunter

Enrollment

432

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution

0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)

DRUG

Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution

Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)

DRUG

Brimonidine 0.2% ophthalmic solution

Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)

Trial Locations (1)

Unknown

El Paso